Skip to main content
Download PDF

The effect of Rosa canina L. and a polyherbal formulation syrup in patients with attention-deficit/hyperactivity disorder: a study protocol for a multicenter randomized controlled trial

Trials volume 23, Article number: 434 (2022) Cite this article

Abstract

Background

Attention-deficit/hyperactivity disorder (ADHD) is the most common behavioral disorder in childhood and adolescence. A number of these patients do not respond to the current pharmacological treatments and there may also be drug side effects. This study aims to determine the efficacy and safety of two herbal medicine products, including Rosa canina L. (RC) and a polyherbal formulation (PHF) syrup, on the clinical manifestations of ADHD in children and adolescents.

Methods

Ninety ADHD patients based on DSM-5 diagnostic criteria will be randomly assigned equally into three groups: (1) RC syrup + methylphenidate (MP), (2) PHF syrup + MP, and (3) placebo + MP according to the inclusion criteria (30 subjects in each group). The syrup dosage is 5cc every 8 h, and MP will have a stabilized dose for 8 weeks during the study. Moreover, Conner’s questionnaires will be completed by the teacher and parents before the intervention and then every 4 weeks. Also, the Child Symptom Inventory-fourth edition (CSI-4) and temperament questionnaires will be completed before the intervention and every 4 weeks until 2 months.

Discussion

This trial is the first experiment to determine the effects of RC and PHF syrups on the clinical manifestations of ADHD in children and adolescents. Our findings provide new insight into the effect of these herbal products on the clinical manifestations of ADHD.

Trial registration

Iranian Registry of Clinical Trials IRCT20190923044855N1. Registered on 14 January 2020. The trial was registered at https://www.irct.ir/.

Peer Review reports

Background

Attention-deficit/hyperactivity disorder (ADHD) belongs to a subset of neuropsychiatric disorders in children and adolescents, which is described by persistent impairing symptoms of inattention, hyperactivity, and impulsivity [1]. More than half of these patients exhibit these symptoms during adulthood [2,3,4]. This disorder is frequently combined with learning problems and also an inability with academic/occupational, familial, and social functioning [1,2,3, 5, 6]. ADHD carries a high risk of comorbidities such as anxiety, affective disorders, substance abuse, and personality disorders. Also, poor education consequences, a great chance for inoccupation, divorcement, or imprisonment are more diagnosed among them compared to the general population [3, 5]. Moreover, mood disorder is reported in 15–75% of children with ADHD and 25% of cases have anxiety [7]. The prevalence rate of ADHD in children is approximately 8–12% all over the world [3]. Treatment strategies for ADHD mainly include pharmacotherapy and psychological and behavioral therapies individually or in combination. Psychostimulant drugs, especially methylphenidate (MP), are highly efficacious and the primary choice of pharmaceutical medications for ADHD treatment [3, 6, 7]. Stimulant medications effectively improve ADHD symptoms in most of these patients; however, about 30% of them do not respond to this class of drug, and there may also be a wide range of drug adverse effects such as loss of appetite, sleep disturbances, and anxiety. Therefore, many parents seek complementary and alternative medicines (CAMs) such as food recommendations, herbal medicine, homeopathy, and exercise for controlling overactivity and inattention of ADHD [7]. Herbal medicine is the most commonly administered CAMs method for ADHD due to its well-tolerance and also parent’s acceptance [8, 9]. There are several mechanisms of action for these medicinal plants associated with the pathogenesis of ADHD, including anxiolytic and antidepressant effects, improvement of cognitive function that help to increase serotonin levels, and central stimulating [7]. Some herbal medicines may be potentially beneficial for ADHD; however, limited information has been reported on their specific effects on this disease in children. So, clinical studies are needed to support their efficacy and safety.

Rosa canina L. (RC) belongs to the Rosacea family, which its different parts such as roots, leaves, and fruits have been used to treat several diseases in traditional medicine for centuries [10]. Preclinical studies have shown that RC has neuroprotective effects when used in combination with other herbs [11, 12]. Moreover, it has been demonstrated that RC extract has anxiolytic properties and can improve recognition memory and depressive-like behavior [13, 14]. Furthermore, we hypothesized that a polyherbal formulation (PHF) syrup that contains Malus domestica Borkh., Ocimum basilicum L., and Vitis vinifera L. extract may have beneficial effects on ameliorating memory and cognitive function and anxiety in children with ADHD.

In an experimental animal model, it is shown that chronic administration of Malus domestica Borkh. fruit juice has valuable antidepressant activity [15]. Ocimum basilicum L. is an edible herb, which has anxiolytic, sedative, and antidepressant-like effects [16, 17]. Also, its neuroprotective properties, especially the improvement of memory and neurological deficit, have been documented previously [18]. Pharmacological studies displayed that Vitis vinifera L. has beneficial effects on cognitive function and neuropsychological status; additionally, it indicates anxiolytic-like activity [19, 20].

Therefore, we designed this randomized clinical trial to evaluate the efficacy and safety of RC and PHF syrups on the clinical manifestations of ADHD in children and adolescents.

Methods

Study design

This study is a randomized, double-blind, placebo and active product controlled, multicenter clinical trial with three parallel treatment arms to compare the efficacy of two herbal products in children and adolescents with ADHD using the Conners’ Parent and Teacher Rating Scale as a primary outcome measure. Secondary outcome measures are comorbid complaints and side effects. After screening and baseline assessments, 90 patients (aged 5–14 years) will receive one of the three treatments for 8 weeks. Outcome assessments will be performed at the baseline, a 4-week treatment period, and the end of treatment on the 8th week. Figure 1 provides details of the study schedule. The reporting of this trial is conducted according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (Fig. 2). The Consolidated Standards of Reporting Trials (CONSORT) has been used as frameworks of methodology for the design of this protocol.

Fig. 1
figure 1

CONSORT flow diagram of the study

Full size image
Fig. 2
figure 2

Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) flowchart of the study

Full size image

The study protocol was reviewed and approved by the Medical Ethics Committee of Iran University of Medical Sciences [session no: IRIUMS.REC. 1398.561] and registered in the Iranian Registry of Clinical Trials [registration code: IRCT20190923044855N1].

Study population

The patients (the children and adolescents aged 5 to 14 years) will be mainly recruited from the three pediatric neurology and psychiatric clinics located at the Rasoul Akram academic hospital, the Firooz Abadi academic hospital, and community clinics in Tehran, Iran. Patients meeting eligibility criteria will be done thoroughly and written consent of the legal representative to participate in the trial will be taken before inclusion. Participants will be randomized, stratified by trial center, to one of the three treatment arms (placebo, RC, and PHF) by randomization software (http://www.randomization.com). The principal investigator (PI) will be situated in each of the study centers to evaluate the implementation of the plan, follow up patients, and deliver checklists and receive and review them and for data collection and entry, as well as respond to patient problems and possible side effects of the drug. Those who meet the inclusion criteria will enroll in the trial and will be randomly allocated into three groups with a 1:1:1 randomization ratio.

Eligibility criteria

Patients will enroll in this trial if they have these criteria:

(1) Male and female children aged 5 to 14 years; (2) parents and children willing and able to follow all study visits; (3) diagnosis of ADHD, according to the DSM-5 diagnostic criteria; (4) treatment with a stabilized dose of oral stimulant medications (e.g., MP) through the study period; and (5) non-use of other alternative and complementary medications that may interact with the herbal product.

Exclusion criteria

Children with any of the following criteria will be excluded from the trial:

(1) History of mental retardation; (2) history of bipolar disorder, psychosis, severe conduct disorder, and autism; and (3) history of neurological diseases, seizures, or other serious medical conditions.

Withdrawal criteria

The study withdrawal criteria are listed as follows:

(1) Parents’ or children’s unwillingness to continue treatment or refusal to participate in the study due to immigration; (2) possible adverse events of treatment; and (3) developing another illness or not taking or misusing the medicine.

The strategies we will use to achieve adequate participant enrolment to reach the target sample size are as follows: educate parents and their children about the trial before asking for consent, make sure they are well aware of the trial, provide written information to parents and children (if required), take the time to answer their questions, and encourage them with regular meetings (face-to-face or by phone) to solve the issues.

The strategies we will use to promote participant retention and complete follow-up are as follows: take the time to answer their questions, encourage them with regular meetings (face-to-face or by phone) to solve the issues, schedule follow-up visits to coincide with routine visits to the office or clinic and facilitate patients’ preferences, and make every effort to locate lost patients.

Participants who withdraw from the trial will be followed up, according to the routine clinical practices.

Sample size calculation

The sample size was determined according to the previous study [21] using two-mean comparison formula. By considering type I error (0.05) and type II (0.2) and the mean change (SD) of the clinical scale of ADHD score in treatment and placebo groups ( −2.8 ±1.5 and −1.2 ±2.5, respectively) and the attrition rate of 15%, the sample size was calculated 30 subjects in each group (a total of 90 patients). Patients will be allocated to groups using the block randomization method.

Randomization

The subjects who meet the eligibility criteria will be randomly divided into the intervention and placebo groups using the permuted block randomization method. Moreover, stratified randomization will be used to match the subjects based on the age distributions (5–10 and 10–14 years old). Participants will be randomly assigned to three treatment groups of (1) RC syrup + MP, (2) PHF syrup + MP, and (3) placebo + MP. Then, they will be followed up for 8 weeks. In this trial, random allocation will be performed according to Sealed Envelope tools, by a study statistician through randomization software. Only the person who is located in the selected center will give the patient medicine based on the random allocation sequence list, which will be made.

Blinding

Both investigators and participants will be blinded to the study design during the implementation of the plan. A sequence allocation list is used to reveal a participant’s allocated intervention during the trial. The unblinding circumstances will be executed in a life-threatening situation like shock or severe drug reaction.

Intervention

RC, PHF, and placebo are in the form of syrup and will be provided by a botanist in the herbarium center of the pharmacy school, Shahid Beheshti University of Medical Sciences, Tehran, Iran. RC contains Rosa canina L. extract; PHF contains Malus domestica Borkh., Ocimum basilicum L., and Vitis vinifera L. extract; and placebo is considered sucrose.

Ninety children and adolescents with ADHD will be invited to the study and randomly assigned to three groups. Subjects will be required to consume 5 cc per day every 8 h according to the recommended dosage for children in the syrup brochure.

The syrups will be prepared in 250 cc glassware and will suffice for about a month. The syrups are identical in size, color, and shape. Any possible complications regarding the numbers of syrups and package will be recorded. Furthermore, the study progress will be pursued by recruiting the subjects every 4 weeks (Fig. 2).

Adherence

At the first visit, the participants will receive interventions and will be asked to bring all bottles of eaten syrups every month. Returned supplements will be observed to evaluate the level of compliance and adherence to the intervention.

Patient safety

All participants will be monitored by PI and any probable adverse events (AEs) will be recorded in the case report form (CRF) carefully, during the study period. Furthermore, at the first visit, the phone number of the PI will be given to each participant and it will also be written on the syrup label. The herbal medicines in this study do not have significant side effects, but in case of an adverse event, the PI will collect, report, and manage any adverse events to compensate them from trial participation.

Study outcomes

Primary outcomes

The primary objective of this research is to determine the efficacy and safety of these herbal medicine products on Conner’s score from baseline to 8 weeks after inclusion (including attention and activity function levels and socio-educational functioning levels).

Secondary outcomes

The secondary outcomes of this study include the occurrence of adverse events, changes in sleep score, appetite habitus, and comorbidities (e.g., anxiety, depression, and obsessive-compulsive disorders) at the end of the study in comparison with the baseline values.

Procedure

At the beginning of the study, goals, methods, and benefits of the trial will be clarified to the parents and participants and an informed consent form will be provided to them. Conners Comprehensive Behavior Rating Scales (Conners CBRS) will be used for obtaining information about several important domains of participant’s behavior, including behavioral, communal, educational topics, and their symptoms. The validity and reliability of this questionnaire were approved previously [22, 23]. In this study, two of Conner’s CBRS questionnaires will be completed (both parent and teacher rating scales):

  1. 1.

    Conners’ Parent Rating Scale (CPRS), a tool for effectively collecting parental reports of child behavior problems

  2. 2.

    Conners’ Teacher Rating Scale (CTRS), a tool for obtaining teacher reports of children’s behavior in the classroom [24,25,26,27]

In addition to these questionnaires, the Child Symptom Inventory-4 (CSI-4) questionnaire, which was validated previously [28, 29], will be used to evaluate attention problems in the study participants. The CSI-4 questionnaire is a behavior rating scale that is used for the diagnosis and also severity assessment of ADHD in children between 5 and 12 years old [30, 31]. The temperament determinant questionnaire is also another validated questionnaire used in this study [32].

These questionnaires will be completed before the intervention and then Conner’s questionnaires will just be used every 4 weeks by the teacher and parents during the study. The interviewer will evaluate children signs and symptoms every 4 weeks for 2 months. There is no specific intervention to change the participants’ lifestyle (diet, sleep, activity, etc.).

Lifestyle changes

No intervention is made in the patient’s living conditions to evaluate the drug’s efficacy.

Patients will not be deprived of their daily treatment (MP/Ritalin). In addition, they will use one of the interventions. To prevent drug interactions between Ritalin and herbal syrups, the patients will consume the syrups 2 h after taking MP/Ritalin. Patients are not allowed to use other herbal medicines during the trial. We will urge patients to drink the syrup three times a day.

Data management

Data will be managed jointly by the study centers. All the data will be recorded with printed and electronic case report forms (CRFs). After each assessment, the identifiers (e.g., name and birth date) will be anonymized, coded, and stored on a secure server. The files will be backed up on a password-protected computer. The project team designed and prepared the trial and will disseminate the results. The team will meet regularly to discuss the progress of the study. Only outcome assessors have access to CRFs and will perform the double-data entry.

Data analysis

The normal distribution of continuous variables will be assessed using the Kolmogorov-Smirnov test. Continuous and categorical variables will be presented as mean (standard deviation) and number (%), respectively. The chi-square or Fisher’s exact test will be used to analyze the qualitative variables. Continuous baseline characteristics across the study groups will be tested using the ANOVA test. Missing data will be imputed using the multiple regression imputation method. A two-way repeated measures ANOVA (RMA) will be employed to assess the effect of intervention using time-group interaction. The significance level will be considered less than 0.05. Data will be analyzed using SPSS 21 statistical software.

Data accessibility

The final trial dataset will be only available to the PI and study statistician (MQ), and other investigators will have limited access. Finally, the study results will be presented only in the publication. Moreover, data can be shared after a reasonable request to the corresponding author.

Discussion

To the best of our knowledge, this is a novel multicenter study designed for the first time to evaluate the therapeutic effects of two herbal formulations on the treatment of children and adolescents with ADHD and also their comorbidity, appetite, and sleep.

The long-term use and side effects of conventional medications are a concern for parents, so they are increasingly looking for treatment options of CAMs [7]. A number of patients with ADHD diagnosis are frequently using CAMs, including dietary modifications, nutritional supplementation, and just herbal medicine alone or along with current pharmacological treatments in order to manage hyperkinetic and concentration disorders [2]. Diet, exercise, and nutritional supplements all have some potential benefits for a child with ADHD. Herbal remedies, which have been shown to have good effects on restlessness, anxiety, and depression, can also be proper options; however, more research is needed [7]. Moreover, the role of chronic inflammation and oxidative stress has been noted in ADHD. Dietary polyphenols have antioxidant and immunomodulatory properties; so, they may be useful in the management of ADHD [33].

Different herbal preparations have been evaluated in clinical trials as a treatment for children and adolescents with ADHD. The findings propose that some of them may be as effective as MP [6]. RC has some beneficial effects on anxiety, recognition, memory, and depressive-like behaviors [13, 14]. Numerous studies have shown that the ingredients in PHF syrup have considerable ameliorating effects on anxiety, depression, and memory [15,16,17,18,19,20]. So, the authors hypothesized that RC and PHF syrups will be valuable for the management of ADHD.

Availability of data and materials

This trial does not involve the storage of biological specimens. The data and materials during the current study can be shared after a reasonable request to the corresponding author. Public access to the full protocol can be accessed as follows: https://www.irct.ir/ (Registration number: IRCT20190923044855N1).

Abbreviations

ADHD:

Attention-deficit/hyperactivity disorder

RC:

Rosa canina L.

PHF:

Polyherbal formulation

DSM-5:

Diagnostic and statistical manual of mental disorders

MP:

Methylphenidate

CSI-4:

Child Symptom Inventory-fourth edition

CAMs:

Complementary and alternative medicines

PI:

Principal investigator

SD:

Standard deviation

CI:

Confidence interval

AEs:

Adverse events

CRF:

Case report form

Conners CBRS:

Conners Comprehensive Behavior Rating Scales

CTRS:

Conners’ Teacher Rating Scale

CPRS:

Conners’ Parent Rating Scale

References

  1. Polanczyk G, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8.

    Article  Google Scholar 

  2. Sarris J, et al. Complementary medicines (herbal and nutritional products) in the treatment of attention deficit hyperactivity disorder (ADHD): a systematic review of the evidence. Complement Ther Med. 2011;19(4):216–27.

    Article  Google Scholar 

  3. Luo Y, et al. A review of heterogeneity in attention deficit/hyperactivity disorder (ADHD). Front Human Neurosci. 2019;13:42.

    Article  CAS  Google Scholar 

  4. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209–25.

    Article  Google Scholar 

  5. Lee SS, et al. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31(3):328–41.

    Article  Google Scholar 

  6. Wong YW, Kim D-G, Lee J-Y. Traditional oriental herbal medicine for children and adolescents with ADHD: a systematic review. Evid Based Complement Altern Med. 2012;2012. https://doi.org/10.1155/2012/520198.

  7. Pellow J, Solomon EM, Barnard CN. Complementary and alternative medical therapies for children with attention-deficit/hyperactivity disorder (ADHD). Altern Med Rev. 2011;16(4):323–37.

    PubMed  Google Scholar 

  8. Shakibaei F, et al. Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial. Complement Ther Clin Pract. 2015;21(2):61–7.

    Article  Google Scholar 

  9. Gromball J, et al. Hyperactivity, concentration difficulties and impulsiveness improve during seven weeks’ treatment with valerian root and lemon balm extracts in primary school children. Phytomedicine. 2014;21(8-9):1098–103.

    Article  Google Scholar 

  10. Selahvarzian A, et al. Medicinal properties of Rosa canina L. Herbal Med J. 2018;3(2):77–84.

    Google Scholar 

  11. Daneshmand P, et al. Neuroprotective effects of herbal extract (Rosa canina, Tanacetum vulgare and Urtica dioica) on rat model of sporadic Alzheimer’s disease. Avicenna J Med Biotechnol. 2016;8(3):120–5.

    PubMed  PubMed Central  Google Scholar 

  12. Vafaee F, et al. Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats. Neural Regen Res. 2012;7(27):2085–91.

    PubMed  PubMed Central  Google Scholar 

  13. Farajpour R, et al. Chronic administration of Rosa canina hydro-alcoholic extract attenuates depressive-like behavior and recognition memory impairment in diabetic mice: a possible role of oxidative stress. Med Princ Pract. 2017;26(3):245–50.

    Article  Google Scholar 

  14. Nemati Z, et al. Effect of a hydroalcoholic extract of Rosa canina flowers on anxiety in rats. Neurophysiology. 2015;47(2):133–7.

    Article  Google Scholar 

  15. Lobo AR, Satish S. An investigation on anti-depressant activity of fresh fruit juice of Malus domestica in experimental animal models; 2019.

    Google Scholar 

  16. Rabbani M, Sajjadi SE, Vaezi A. Evaluation of anxiolytic and sedative effect of essential oil and hydroalcoholic extract of Ocimum basilicum L. and chemical composition of its essential oil. Res Pharmaceut Sci. 2015;10(6):535.

    Google Scholar 

  17. Ali SS, et al. The antidepressant-like effect of Ocimum basilicum in an animal model of depression. Biotech Histochem. 2017;92(6):390–401.

    Article  CAS  Google Scholar 

  18. Singh V, Krishan P, Shri R. Improvement of memory and neurological deficit with Ocimum basilicum L. extract after ischemia reperfusion induced cerebral injury in mice. Metab Brain Dis. 2018;33(4):1111–20.

    Article  CAS  Google Scholar 

  19. Aslam M, Sultana N. Evaluation of anxiolytic-like activity of Vitis vinifera juice in mice. Avicenna J Phytomed. 2016;6(3):344–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Calapai G, et al. A randomized, double-blinded, clinical trial on effects of a Vitis vinifera extract on cognitive function in healthy older adults. Front Pharmacol. 2017;8:776.

    Article  Google Scholar 

  21. Bae S, Park S, Han DH. A mixed herbal extract as an adjunctive therapy for attention deficit hyperactivity disorder: a randomized placebo-controlled trial. Integr Med Res. 2021;10(3):100714.

    Article  Google Scholar 

  22. Conners CK, et al. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnormal Child Psychol. 1998;26(4):257–68.

    Article  CAS  Google Scholar 

  23. Conners CK, et al. Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnormal Child Psychol. 1998;26(4):279–91.

    Article  CAS  Google Scholar 

  24. Smyth AC, Meier ST. Evaluating the psychometric properties of the conners adult ADHD rating scales. J Attention Disord. 2019;23(10):1111–8.

    Article  Google Scholar 

  25. Izzo VA, Donati MA, Primi C. Assessing ADHD through the multi-informant approach: the contribution of the Conners’3 scales. J Attent Disord. 2019;23(6):641–50.

    Article  Google Scholar 

  26. Abdekhodaie Z, Tabatabaei SM, Gholizadeh M. The investigation of ADHD prevalence in kindergarten children in northeast Iran and a determination of the criterion validity of Conners’ questionnaire via clinical interview. Res Dev Disabil. 2012;33(2):357–61.

    Article  Google Scholar 

  27. Shaked D, et al. Reliability and validity of the Conners’ continuous performance test. Appl Neuropsychol Adult. 2020;27(5):478-87.

  28. Mohamadesmaiel E, Alipour A. A preliminary study on the reliability, validity and cut off points of the disorders of children symptom inventory-4 (CSI-4). J Except Child. 2002;2(3):239–54.

    Google Scholar 

  29. Sprafkin J, et al. Further evidence of reliability and validity of the Child Symptom Inventory-4: parent checklist in clinically referred boys. J Clin Child Adolesc Psychol. 2002;31(4):513–24.

    Article  Google Scholar 

  30. Shooshtary MH, et al. The prevalence of attention deficit hyperactivity disorder in Iran: a systematic review. Iran J Psychiatry. 2010;5(3):88.

    PubMed  PubMed Central  Google Scholar 

  31. Mohammad Esmaeel E. Adaptation and standardization of child symptom inventory-4 (CSI-4). J Except Child. 2007;7(1):79–96.

    Google Scholar 

  32. Salmannezhad H, et al. Design and validation of Mizaj identification questionnaire in Persian Medicine. Iran Red Crescent Med J. 2018;20(11):9.

  33. Verlaet AA, et al. Rationale for dietary antioxidant treatment of ADHD. Nutrients. 2018;10(4):405.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research has been supported by the Iran University of Medical Sciences (grant no. 98-2-63-15165). The funder has no role in the study design, collection, analysis, and interpretation of the data; the writing of the paper; and the decision to submit the paper.

Author information

Authors and Affiliations

  1. Department of Traditional Medicine, Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran

    Haide Golsorkhi, Saeideh Sabbaghzadegan & Majid Dadmehr

  2. Department of Traditional Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran

    Haide Golsorkhi, Saeideh Sabbaghzadegan & Majid Dadmehr

  3. Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

    Mostafa Qorbani

  4. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Mostafa Qorbani

  5. Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Mohammad Kamalinejad

  6. Researcher of Persian Medicine, Private clinic, Tehran, Iran

    Mohsen Bahrami

  7. Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

    Mohammad Vafaee-Shahi

  8. Department of Pediatrics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

    Hadi Montazerlotfelahi

  9. Researcher of Clinical Psychology, Private clinic, Tehran, Iran

    Elham Abniki

Authors
  1. Haide Golsorkhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mostafa Qorbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Kamalinejad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saeideh Sabbaghzadegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohsen Bahrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohammad Vafaee-Shahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hadi Montazerlotfelahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elham Abniki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Majid Dadmehr
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MB and MK designed the idea of this work. HG, MD, and MVS coordinated the study. MQ advised on the statistical analysis. HG, HM, MVS, and EA organized participant management and data collection. HG, MD, and SS drafted the manuscript. The manuscript has been read and approved by all authors.

Corresponding author

Correspondence to Majid Dadmehr.

Ethics declarations

Ethics approval and consent to participate

The Ethics Committee of Iran University of Medical Sciences has approved the study protocol [session no: IRIUMS.REC. 1398.561]. The parent or guardian of all eligible participants will be informed of the study’s details and all the benefits and risks that participants may take from this trial by PI. They will be asked if they agree to use their children’s data on the consent form should they choose to withdraw from the trial. They will also be asked for permission for the research team to share relevant data with people from the universities taking part in the research or from regulatory authorities. In addition, all researchers were trained and signed a pledge to protect the confidentiality of study participants. At the beginning of the study, a written informed consent form will be obtained from a parent or guardian for participants (in two copies, one for trial participants and another for the dataset).

These materials are available from the corresponding author on request. Any changes to the protocol or severe adverse events will be reported to the data monitoring committee. Confidentiality of the data and the results of monitoring will be protected.

Consent for publication

Study results will be published by the investigators in peer-reviewed journals or presented at conferences.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Golsorkhi, H., Qorbani, M., Kamalinejad, M. et al. The effect of Rosa canina L. and a polyherbal formulation syrup in patients with attention-deficit/hyperactivity disorder: a study protocol for a multicenter randomized controlled trial. Trials 23, 434 (2022). https://doi.org/10.1186/s13063-022-06297-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13063-022-06297-7

Keywords

Trials

ISSN: 1745-6215